Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis
Allison A. Throm, … , Lauren M. Pachman, Anthony R. French
Allison A. Throm, … , Lauren M. Pachman, Anthony R. French
Published November 15, 2018
Citation Information: JCI Insight. 2018;3(22):e123236. https://doi.org/10.1172/jci.insight.123236.
View: Text | PDF
Research Article Immunology

Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis

  • Text
  • PDF
Abstract

Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with characteristic rash and muscle weakness. To delineate signaling abnormalities in JDM, mass cytometry was performed with PBMCs from treatment-naive JDM patients and controls. NK cell percentages were lower while frequencies of naive B cells and naive CD4+ T cells were higher in JDM patients than in controls. These cell frequency differences were attenuated with cessation of active disease. A large number of signaling differences were identified in treatment-naive JDM patients compared with controls. Classification models incorporating feature selection demonstrated that differences in phospholipase Cγ2 (PLCγ2) phosphorylation comprised 10 of 12 features (i.e., phosphoprotein in a specific immune cell subset) distinguishing the 2 groups. Because NK cells represented 5 of these 12 features, further studies focused on the PLCγ2 pathway in NK cells, which is responsible for stimulating calcium flux and cytotoxic granule movement. No differences were detected in upstream signaling or total PLCγ2 protein levels. Hypophosphorylation of PLCγ2 and downstream mitogen-activated protein kinase-activated protein kinase 2 were partially attenuated with cessation of active disease. PLCγ2 hypophosphorylation in treatment-naive JDM patients resulted in decreased calcium flux. The identification of dysregulation of PLCγ2 phosphorylation and decreased calcium flux in NK cells provides potential mechanistic insight into JDM pathogenesis.

Authors

Allison A. Throm, Joshua B. Alinger, Jeanette T. Pingel, Allyssa L. Daugherty, Lauren M. Pachman, Anthony R. French

×

Figure 1

PBMC percentages in JDM patients and healthy controls.

Options: View larger image (or click on image) Download as PowerPoint
PBMC percentages in JDM patients and healthy controls.
Open circles deno...
Open circles denote treatment-naive patients (n = 17). Filled squares denote healthy controls (n = 17). (A) Percentage of PBMC population in treatment-naive patients and controls for higher frequency (left panel) and lower frequency (right panel) immune cell types (1-way ANOVA: F = 7.429, P < 0.001; naive B cells: t = 7.459, P < 0.05; naive CD4+ T cells: t = 6.561, P < 0.05; NK cells: t = 4.415, P < 0.05). (B) Percentage of PBMC populations in paired treatment-naive and clinically inactive disease patient samples for higher frequency (left panel) and lower frequency (right panel) immune cell types (1-way ANOVA: F = 36.15, P < 0.005; naive B cells: t = 6.986, P < 0.05, and n = 11 paired patient samples). ×’s denote patients after achieving clinically inactive disease (n = 11). Error bars represent the mean ± SEM. *P < 0.05 after appropriate multiple hypothesis correction.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts